Identification of cbx3 and abca5 as putative biomarkers for tumor stem cells in osteosarcoma

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Saini, Vaibhav ^a,c   Hose, Curtis D ^b   Monks, Anne ^b   Nagashima, Kunio ^b   Han, Bingnan ^b   Newton, Dianne L ^b   Millione, Angelena ^b   Shah, Jalpa ^b   Hollingshead, Melinda G ^a   Hite, Karen M ^b   Burkett, Mark W ^b   Delosh, Rene M ^b   Silvers, Thomas E ^b   Scudiero, Dominic A ^b   Shoemaker, Robert H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A5; ALDEHYDE DEHYDROGENASE; ALVESPIMYCIN; AZACITIDINE; BIOLOGICAL MARKER; BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD24 ANTIGEN; CHROMOBOX PROTEIN HOMOLOG 3; CISPLATIN; DASATINIB; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; HERMES ANTIGEN; IMATINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NESTIN; NUCLEAR PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; SORAFENIB; THIOSEMICARBAZONE DERIVATIVE; TOPOTECAN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; DRUG SENSITIVITY; EPIGENETICS; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; AZACITIDINE; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMORAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84864542596     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041401     Document Type: Article

References (51)

1. Ek ET, Dass CR, Choong PF, ((2006)) Commonly used mouse models of osteosarcoma. Crit Rev Oncol Hematol 60:: 1--8.
2. Fan TM, ((2010)) Animal models of osteosarcoma. Expert Rev Anticancer Ther 10:: 1327--1338.
3. Saini V, Shoemaker RH, ((2010)) Potential for therapeutic targeting of tumor stem cells. Cancer Sci 101:: 16--21.
4. Hurt EM, Chan K, Serrat MA, Thomas SB, Veenstra TD, et al. ((2010)) Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells 28:: 390--398.
5. Wang L, Park P, Lin CY, ((2009)) Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther 8.
6. Honoki K, Fujii H, Kubo A, Kido A, Mori T, et al. ((2010)) Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 24:: 501--505.
7. Takebe N, Harris PJ, Warren RQ, Ivy SP, ((2011)) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:: 97--106.
8. Dean M, Fojo T, Bates S, ((2005)) Tumour stem cells and drug resistance. Nat Rev Cancer 5:: 275--284.
9. Ding XW, Wu JH, Jiang CP, ((2010)) ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86:: 631--637.
10. Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, et al. ((2008)) ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer 7:: 87.
11. Wang L, Park P, Zhang H, La Marca F, Lin CY, ((2010)) Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer.
12. Moreb JS, ((2008)) Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 3:: 237--246.
13. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, et al. ((2008)) Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10:: R10.
14. Boman BM, Wicha MS, ((2008)) Cancer stem cells: a step toward the cure. J Clin Oncol 26:: 2795--2799.
15. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, et al. ((2008)) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 105:: 13427--13432.
16. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. ((2003)) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:: 5821--5828.
17. Tirino V, Desiderio V, d'Aquino R, De Francesco F, Pirozzi G, et al. ((2008)) Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS ONE 3:: e3469.
18. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, et al. ((2008)) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 3:: e2637.
19. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, et al. ((2008)) Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14:: 4085--4095.
20. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, et al. ((2008)) SOX2 Silencing in Glioblastoma Tumor Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity. Stem Cells.
21. Levings PP, McGarry SV, Currie TP, Nickerson DM, McClellan S, et al. ((2009)) Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 69:: 5648--5655.
22. Murray E, Provvedini D, Curran D, Catherwood B, Sussman H, et al. ((1987)) Characterization of a human osteoblastic osteosarcoma cell line (SAOS-2) with high bone alkaline phosphatase activity. J Bone Miner Res 2:: 231--238.
23. Rodan SB, Imai Y, Thiede MA, Wesolowski G, Thompson D, et al. ((1987)) Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res 47:: 4961--4966.
24. Kawai A, ((1990)) A newly established human osteosarcoma cell line with osteoblastic properties. Clin Orthop Relat Res. pp. 256--267.
25. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, et al. ((2006)) Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 12:: 459--465.
26. Takanashi M, Oikawa K, Fujita K, Kudo M, Kinoshita M, et al. ((2009)) Heterochromatin protein 1gamma epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers. Am J Pathol 174:: 309--316.
27. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, et al. ((2010)) Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28:: 649--660.
28. Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA, ((2011)) The Role of RUNX2 in Osteosarcoma Oncogenesis. Sarcoma 2011:: 282745.
29. Wagner ER, He BC, Chen L, Zuo GW, Zhang W, et al. ((2010)) Therapeutic Implications of PPARgamma in Human Osteosarcoma. PPAR Res 2010:: 956427.
30. Dittmer J, ((2003)) The biology of the Ets1 proto-oncogene. Mol Cancer 2:: 29.
31. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, et al. ((2010)) Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18:: 23--38.
32. Huang P, Kishida S, Cao D, Murakami-Tonami Y, Mu P, et al. ((2011)) The neuronal differentiation factor NeuroD1 downregulates the neuronal repellent factor Slit2 expression and promotes cell motility and tumor formation of neuroblastoma. Cancer Res 71:: 2938--2948.
33. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, et al. ((2010)) CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70:: 4602--4612.
34. Smith GH, Chepko G, ((2001)) Mammary epithelial stem cells. Microsc Res Tech 52:: 190--203.
35. Mathews LA, Hurt EM, Zhang X, Farrar WL, ((2010)) Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells. Mol Cancer 9:: 267.
36. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, et al. ((2009)) Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26:: 433--446.
37. Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, et al. ((2008)) Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer 8:: 300.
38. Gry M, Rimini R, Stromberg S, Asplund A, Ponten F, et al. ((2009)) Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 10:: 365.
39. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. ((2008)) Efficient tumour formation by single human melanoma cells. Nature 456:: 593--598.
40. Huang D, Gao Q, Guo L, Zhang C, Jiang W, et al. ((2009)) Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 18:: 465--473.
41. Hu Y, Wang M, Veverka K, Garcia FU, Stearns ME, ((2007)) The ABCA5 protein: a urine diagnostic marker for prostatic intraepithelial neoplasia. Clin Cancer Res 13:: 929--938.
42. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, et al. ((2011)) Aldehyde Dehydrogenase Activity of Breast Cancer Stem Cells is Primarily Due to Isoform ALDH1A3 and Its Expression is Predictive of Metastasis. Stem Cells.
43. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, et al. ((2008)) Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 6:: 1146--1153.
44. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, et al. ((2009)) Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chemico-Biological Interactions 178:: 48--55.
45. Prasmickaite L, Engesaeter BO, Skrbo N, Hellenes T, Kristian A, et al. ((2010)) Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One 5:: e10731.
46. Schneider-Stock R, Diab-Assef M, Rohrbeck A, Foltzer-Jourdainne C, Boltze C, et al. ((2005)) 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J Pharmacol Exp Ther 312:: 525--536.
47. Rajendran G, Shanmuganandam K, Bendre A, Mujumdar D, Goel A, et al. ((2010)) Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. J Neurooncol.
48. Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, et al. ((2010)) The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 70:: 9494--9504.
49. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, et al. ((1988)) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:: 4827--4833.
50. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, et al. ((2011)) NCBI GEO: archive for functional genomics data sets - 10 years on. Nucleic Acids Res 39:: D1005--1010.
51. Fritsche-Guenther R, Noske A, Ungethum U, Kuban RJ, Schlag PM, et al. ((2010)) De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology 57:: 836--850.